Skip to main content

ORIGINAL RESEARCH article

Front. Bioeng. Biotechnol.
Sec. Bioprocess Engineering
Volume 12 - 2024 | doi: 10.3389/fbioe.2024.1448925

Modulating antibody N-glycosylation through feed additives using a multi-tiered approach

Provisionally accepted
Jaka Kranjc Jaka Kranjc 1Lovro Kramer Lovro Kramer 2*Miha Mikelj Miha Mikelj 2*Marko Anderluh Marko Anderluh 1Anja Pišlar Anja Pišlar 1Matjaž Brinc Matjaž Brinc 2*
  • 1 Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
  • 2 Novartis (Slovenia), Ljubljana, Slovenia

The final, formatted version of the article will be published soon.

    Glycosylation of recombinant proteins is a post-translational modification that affects multiple physicochemical and biological properties of proteins. As such, it is a critical quality attribute that must be carefully controlled during protein production in the pharmaceutical industry. Glycosylation can be modulated by various conditions, including the composition of production media and feeds. In this study, the N-glycosylation-modulating effects of numerous compounds, including metal enzyme cofactors, enzyme inhibitors, and metabolic intermediates, were evaluated. Chinese hamster ovary cells producing three different IgG antibodies were cultivated in a fed-batch mode. First, a one-factor-at-atime experiment was performed in 24-well deep well plates to identify the strongest modulators and appropriate concentration ranges. Then, a full response surface experiment was designed to gauge the effects and interactions of the 14 most effective hit compounds in an Ambr® 15 bioreactor system. A wide range of glycoform content was achieved, with an up to eight-fold increase in individual glycoforms compared to controls. The resulting model can be used to determine modulator combinations that will yield desired glycoforms in the final product.

    Keywords: bioprocess, Glycosylation, modulators, modelling, Chinese hamster ovary, antibody production

    Received: 14 Jun 2024; Accepted: 09 Aug 2024.

    Copyright: © 2024 Kranjc, Kramer, Mikelj, Anderluh, Pišlar and Brinc. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Lovro Kramer, Novartis (Slovenia), Ljubljana, Slovenia
    Miha Mikelj, Novartis (Slovenia), Ljubljana, Slovenia
    Matjaž Brinc, Novartis (Slovenia), Ljubljana, Slovenia

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.